Imperial College London
Portrait Picture

ProfessorAlexanderComninos

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Practice (Endocrinology)
 
 
 
//

Contact

 

+44 (0)20 3313 3242a.comninos

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sharma:2022:10.3389/fendo.2022.972137,
author = {Sharma, B and Koysombat, K and Dhillo, W and Abbara, A},
doi = {10.3389/fendo.2022.972137},
journal = {Frontiers in Endocrinology},
pages = {1--9},
title = {Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment},
url = {http://dx.doi.org/10.3389/fendo.2022.972137},
volume = {13},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Infertility is a major global health issue and is associated with significant psychological distress for afflicted couples. In vitrofertilisation (IVF) utilises supra-physiological doses of stimulatory hormones to induce the growth of multiple ovarian follicles toenable surgical retrieval of several oocytes for subsequent fertilisation and implantation into the maternal endometrium. Thesupra-physiological degree of ovarian stimulation can lead to potential risks during IVF treatment, including ovarianhyperstimulation syndrome (OHSS) and multiple pregnancy.The choice of oocyte maturation trigger, such as human chorionic gonadotrophin (hCG) or gonadotrophin releasing hormoneagonist (GnRHa), can impact both the efficacy of IVF treatment with a bearing on luteal phase hormonal dynamics and thus thedegree of luteal phase support required to maintain optimal pregnancy rates, as well as on safety of treatment with particularrespect to the risk of OHSS. Kisspeptin regulates gonadotrophin releasing hormone (GnRH) release and is therefore a key regulatorof the hypothalamo-pituitary-gonadal (HPG) axis. Kisspeptin has been shown to be requisite for the occurrence of the physiologicalovulatory luteinising hormone (LH) surge. In this review, we discuss the potential use of kisspeptin as a novel trigger of oocytematuration.
AU  - Sharma,B
AU  - Koysombat,K
AU  - Dhillo,W
AU  - Abbara,A
DO  - 10.3389/fendo.2022.972137
EP  - 9
PY  - 2022///
SN  - 1664-2392
SP  - 1
TI  - Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment
T2  - Frontiers in Endocrinology
UR  - http://dx.doi.org/10.3389/fendo.2022.972137
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2022.972137/full
UR  - http://hdl.handle.net/10044/1/99092
VL  - 13
ER  -
Download